Symbols

IMGN(Delisted)

ImmunoGen·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About IMGN

Immunogen, Inc.

A leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer

Industry

Established Date

Listing Date

11/17/1989

Exchange

NASDAQ Stock Exchange

Full-time Employees

277

Fiscal Year Ends

12-31

Website

www.immunogen.com

Security Type

Common stock

Office address

830 Winter Street, Waltham, MA 02451

Business

Introduction

ImmunoGen, Inc., formed in Massachusetts in 1981, focuses on the development of antibody-based anti-cancer therapies. The company utilizes its Proprietary antibody-drug conjugation technology and ADC technology for the treatment of cancer. ADC technology contains an antibody that, once the ADC binds to the target, attaches to the cancer cell, binding one of its powerful anticancer agents as a "payload" to kill the cancer cell. ADC is an expanded approach to treating cancer, with two approved treatments and a doubling of the number of agents compared to the past five years.

Company Financials

EPS

IMGN has released its 2023 Q3 earnings. EPS was reported at 0.1, versus the expected 0.04, beating expectations. The chart below visualizes how IMGN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

IMGN has released its 2023 Q3 earnings report, with revenue of 113.42M, reflecting a YoY change of 637.72%, and net profit of 30.75M, showing a YoY change of 139.54%. The Sankey diagram below clearly presents IMGN's revenue sources and cost distribution.